Literature DB >> 28576705

The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.

F Giesert1, L Glasl2, A Zimprich2, L Ernst2, G Piccoli3, C Stautner2, J Zerle2, S M Hölter2, D M Vogt Weisenhorn1, W Wurst4.   

Abstract

The aim of the present study was to further explore the in vivo function of the Leucine-rich repeat kinase 2 (LRRK2)-gene, which is mutated in certain familial forms of Parkinson's disease (PD). We generated a mouse model harboring the disease-associated point mutation R1441C in the GTPase domain of the endogenous murine LRRK2 gene (LRRK2 R1441C line) and performed a comprehensive analysis of these animals throughout lifespan in comparison with an existing knockdown line of LRRK2 (LRRK2 knockdown line). Animals of both lines do not exhibit severe motor dysfunction or pathological signs of neurodegeneration neither at young nor old age. However, at old age the homozygous LRRK2 R1441C animals exhibit clear phenotypes related to the prodromal phase of PD such as impairments in fine motor tasks, gait, and olfaction. These phenotypes are only marginally observable in the LRRK2 knockdown animals, possibly due to activation of compensatory mechanisms as suggested by in vitro studies of synaptic transmission. Thus, at the organismal level the LRRK2 R1441C mutation does not emerge as a loss of function of the protein, but induces mutation specific deficits. Furthermore, judged by the phenotypes presented, the LRRK2-R1441C knock-in line is a valid preclinical model for the prodromal phase of PD.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  Behavioral phenotyping; Genetic mouse model of Parkinson's disease; Knock-out–knock-in models; Neurodegenertion; Prodromal symptoms

Mesh:

Substances:

Year:  2017        PMID: 28576705     DOI: 10.1016/j.nbd.2017.05.013

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  10 in total

Review 1.  The role of Rab GTPases in the pathobiology of Parkinson' disease.

Authors:  Luis Bonet-Ponce; Mark R Cookson
Journal:  Curr Opin Cell Biol       Date:  2019-05-01       Impact factor: 8.382

2.  Nigrostriatal pathology with reduced astrocytes in LRRK2 S910/S935 phosphorylation deficient knockin mice.

Authors:  Ye Zhao; Shikara Keshiya; Farzaneh Atashrazm; Jianqun Gao; Lars M Ittner; Dario R Alessi; Glenda M Halliday; Yuhong Fu; Nicolas Dzamko
Journal:  Neurobiol Dis       Date:  2018-09-05       Impact factor: 5.996

Review 3.  The prodromes of Parkinson's disease.

Authors:  Richard Nathaniel Rees; Alastair John Noyce; Anette Schrag
Journal:  Eur J Neurosci       Date:  2018-12-05       Impact factor: 3.386

4.  The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4.

Authors:  Natalja Funk; Marita Munz; Thomas Ott; Kathrin Brockmann; Andrea Wenninger-Weinzierl; Ralf Kühn; Daniela Vogt-Weisenhorn; Florian Giesert; Wolfgang Wurst; Thomas Gasser; Saskia Biskup
Journal:  Sci Rep       Date:  2019-03-14       Impact factor: 4.379

5.  Tremorgenic effects and functional metabolomics analysis of lolitrem B and its biosynthetic intermediates.

Authors:  Priyanka Reddy; Simone Rochfort; Elizabeth Read; Myrna Deseo; Emily Jaehne; Maarten Van Den Buuse; Kathryn Guthridge; Martin Combs; German Spangenberg; Jane Quinn
Journal:  Sci Rep       Date:  2019-06-27       Impact factor: 4.379

Review 6.  Pathological Functions of LRRK2 in Parkinson's Disease.

Authors:  Ga Ram Jeong; Byoung Dae Lee
Journal:  Cells       Date:  2020-11-30       Impact factor: 6.600

Review 7.  LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease.

Authors:  Eunice Eun Seo Chang; Philip Wing-Lok Ho; Hui-Fang Liu; Shirley Yin-Yu Pang; Chi-Ting Leung; Yasine Malki; Zoe Yuen-Kiu Choi; David Boyer Ramsden; Shu-Leong Ho
Journal:  Transl Neurodegener       Date:  2022-02-14       Impact factor: 8.014

8.  Parkinson-causing mutations in LRRK2 impair the physiological tetramerization of endogenous α-synuclein in human neurons.

Authors:  Luis Fonseca-Ornelas; Jonathan M S Stricker; Stephanie Soriano-Cruz; Beatrice Weykopf; Ulf Dettmer; Christina R Muratore; Clemens R Scherzer; Dennis J Selkoe
Journal:  NPJ Parkinsons Dis       Date:  2022-09-16

Review 9.  Animal Model for Prodromal Parkinson's Disease.

Authors:  Tomoyuki Taguchi; Masashi Ikuno; Hodaka Yamakado; Ryosuke Takahashi
Journal:  Int J Mol Sci       Date:  2020-03-13       Impact factor: 5.923

Review 10.  Animal models of Parkinson's disease: a guide to selecting the optimal model for your research.

Authors:  Joana Lama; Yazead Buhidma; Edward J R Fletcher; Susan Duty
Journal:  Neuronal Signal       Date:  2021-12-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.